Meticillin-resistant Staphylococcus pseudintermedius: Clinical challenge and treatment options

Veterinary Dermatology

Volumn 23, Issue 4, 2012, Pages

  Frank, Linda A ^a   Loeffler, Anette ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; METICILLIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLASSIFICATION; DRUG EFFECT; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; METHICILLIN; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

ANIMALIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84864142446     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01047.x     Document Type: Article

References (103)

1. Gortel K, Campbell KL, Kakoma I et al. Methicillin resistance among staphylococci isolated from dogs. Am J Vet Res 1999; 60: 1526-1530.
2. van Duijkeren E, Catry B, Greko C et al. [Scientific Advisory Group on Antimicrobials (SAGAM)]. Review on methicillin-resistant Staphylococcus pseudintermedius. J Antimicrob Chemother 2011; 66: 2705-2714.
3. Chanchaithong P, Prapasarakul N. Biochemical markers and protein pattern analysis for canine coagulase-positive staphylococci and their distribution on dog skin. J Microbiol Methods 2011; 86: 175-181.
4. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997; 10: 781-791.
5. Couto I, de Lencastre H, Severina E et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 1996; 2: 377-391.
6. Tsubakishita S, Kuwahara-Arai K, Sasaki T et al. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrob Agents Chemother 2010; 54: 4352-4359.
7. Loeffler A, Linek M, Moodley A et al. First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Vet Dermatol 2007; 18: 412-421.
8. Cain CL, Morris DO, O'Shea K et al. Genotypic relatedness and phenotypic characterization of Staphylococcus schleiferi subspecies in clinical samples from dogs. Am J Vet Res 2011; 72: 96-102.
9. Kania SA, Williamson NL, Frank LA et al. Methicillin resistance of staphylococci isolated from the skin of dogs with pyoderma. Am J Vet Res 2004; 65: 1265-1268.
10. Epstein CR, Yam WC, Peiris JS et al. Methicillin-resistant commensal staphylococci in healthy dogs as a potential zoonotic reservoir for community-acquired antibiotic resistance. Infect Genet Evol 2009; 9: 283-285.
11. Harbarth S, Huttner B, Gervaz P et al. Risk factors for methicillin-resistant Staphylococcus aureus surgical site infection. Infect Control Hosp Epidemiol 2008; 29: 890-893.
12. Perreten V, Kadlec K, Schwarz S et al. Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010; 65: 1145-1154.
13. Ruscher C, Lübke-Becker A, Wleklinski CG et al. Prevalence of methicillin-resistant Staphylococcus pseudintermedius isolated from clinical samples of companion animals and equidaes. Vet Microbiol 2009; 136: 197-201.
14. Lloyd DH, Lamport AI, Freeney C. Sensitivity to antibiotics amongst cutaneous and mucosal isolates of canine pathogenic staphylococci in the UK, 1980-96. Vet Dermatol 1996; 7: 171-175.
15. Pellerin JL, Bourdeau P, Sebbag H et al. Epidemiosurveillance of antimicrobial compound resistance of Staphylococcus intermedius clinical isolates from canine pyodermas. Comp Immunol Microbiol Infect Dis 1998; 21: 115-133.
16. Holm BR, Petersson U, Mörner A et al. Antimicrobial resistance in staphylococci from canine pyoderma: a prospective study of first-time and recurrent cases in Sweden. Vet Rec 2002; 151: 600-605.
17. Ganiere JP, Medaille C, Mangion C. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. J Vet Med B 2005; 52: 25-31.
18. Morris DO, Rook KA, Shofer FS et al. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003-04). Vet Dermatol 2006; 17: 332-337.
19. Bryan J, Frank L, Rohrbach B et al. Treatment outcome of dogs with meticillin-resistant and meticillin-susceptible Staphylococcus pseudintermedius pyoderma. Vet Dermatol 2012; 23: 361-e65.
20. Fitzgerald JR. The Staphylococcus intermedius group of bacterial pathogens: species re-classification, pathogenesis and the emergence of meticillin resistance. Vet Dermatol 2009; 20: 490-495.
21. Huerta B, Maldonado A, Ginel PJ et al. Risk factors associated with the antimicrobial resistance of staphylococci in canine pyoderma. Veterinary Microbiol 2011; 150: 302-308.
22. Nienhoff U, Kadlec K, Chaberny IF et al. Methicillin-resistant Staphylococcus pseudintermedius among dogs admitted to a small animal hospital. Vet Microbiol 2011; 150: 191-197.
23. Couto N, Pomba C, Moodley A et al. Prevalence of meticillin-resistant staphylococci among dogs and cats at a veterinary teaching hospital in Portugal. Vet Rec 2011; 169: 72.
24. Pinchbeck LR, Cole LK, Hillier A et al. Genotypic relatedness of staphylococcal strains isolated from pustules and carriage sites in dogs with superficial bacterial folliculitis. Am J Vet Res 2006; 67: 1337-1346.
25. Peacock SJ, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 2001; 9: 605-610.
26. Mann PH. Antibiotic sensitivity testing and bacteriophage typing of staphylococci found in the nostrils of dogs and cats. J Am Vet Med Assoc 1959; 134: 469-470.
27. Adekeye JD. Studies on possible cross transmission of mercuric chloride resistant Staphylococcus aureus between dogs and kennel attendants. Int J Zoonoses 1981; 8: 72-76.
28. Guardabassi L, Loeber ME, Jacobson A. Transmission of multiple antimicrobial-resistant Staphylococcus intermedius between dogs affected by deep pyoderma and their owners. Vet Microbiol 2004; 98: 23-27.
29. Talan DA, Staatz D, Staatz A et al. Frequency of Staphylococcus intermedius as human nasopharyngeal flora. J Clin Microbiol 1989; 27: 2393.
30. Mahoudeau I, Delabranche X, Prevost G et al. Frequency of isolation of Staphylococcus intermedius from humans. J Clin Microbiol 1997; 35: 2153-2154.
31. Tanner MA, Everett CL, Youvan DC. Molecular phylogenetic evidence of noninvasive zoonotic transmission of Staphylococcus intermedius from a canine pet to a human. J Clin Microbiol 2000; 38: 1628-1631.
32. Pottumarthy S, Schapiro JM, Prentice JL et al. Clinical isolates of Staphylococcus intermedius masquerading as methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2004; 42: 5881-5884.
33. Kempker R, Mangalat D, Kongphet-Tran T et al. Beware of the pet dog: a case of Staphylococcus intermedius infection. Am J Med Sci 2009; 338: 425-427.
34. Stegmann R, Burnens A, Maranta CA et al. Human infection associated with methicillin-resistant Staphylococcus pseudintermedius ST71. J Antimicrob Chemother 2010; 65: 2047-2048.
35. Sasaki T, Kikuchi K, Tanaka Y et al. Methicillin-resistant Staphylococcus pseudintermedius in a veterinary teaching hospital. J Clin Microbiol 2007; 45: 1118-1125.
36. Ishihara K, Shimokubo N, Sakagami A et al. Occurrence and molecular characteristics of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius in an academic veterinary hospital. Appl Environ Microbiol 2010; 76: 5165-5174.
37. Morris DO, Boston RC, O'Shea K et al. The prevalence of carriage of meticillin-resistant staphylococci by veterinary dermatology practice staff and their respective pets. Vet Dermatol 2010; 21: 400-407.
38. Paul NC, Moodley A, Ghibaudo G et al. Carriage of methicillin-resistant Staphylococcus pseudintermedius in small animal veterinarians: indirect evidence of zoonotic transmission. Zoonoses Public Health 2011; 58: 533-539.
39. Frank LA, Kania SA, Kirzeder EM et al. Risk of colonization or gene transfer to owners of dogs with meticillin-resistant Staphylococcus pseudintermedius. Vet Dermatol 2009; 20: 496-501.
40. Soedarmanto I, Kanbar T, Ulbegi-Mohyla H et al. Genetic relatedness of methicillin-resistant Staphylococcus pseudintermedius (MRSP) isolated from a dog and the dog owner. Res Vet Sci 2011; 91: e25-e27.
41. Loeffler A, Pfeiffer DU, Lindsay JA et al. Lack of transmission of methicillin-resistant Staphylococcus aureus (MRSA) between apparently healthy dogs in a rescue kennel. Vet Microbiol 2010; 141: 178-181.
42. Frank LA, Kunkle GA. Comparison of the efficacy of cefadroxil and generic and proprietary cephalexin in the treatment of pyoderma in dogs. J Am Vet Med Assoc 1993; 203: 530-533.
43. Scott DW, Miller WH, Griffin CE. Bacterial skin diseases. In: Muller and Kirk's Small Animal Dermatology, 6th editionn. Philadelphia, PA: W. B. Saunders Co., 2001: 274-335.
44. WHO-AGISAR 2009. Accessed March 16, 2012.
45. Jones RD, Kania SA, Rohrbach BW et al. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1, 772 samples (2001-2005). J Am Vet Med Assoc 2007; 230: 221-227.
46. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52: 1156-1163.
47. Greene CE. Antimicrobial drug formulary. In: Greene CE, ed. Infectious Diseases of the Dog and Cat, 3rd edition. Philadelphia, PA: W. B. Saunders Co., 2006: 1186-1333.
48. Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin North Am 2006; 90: 1223-1255.
49. Ramilo O, Kinane BT, McCracken GH. Chloramphenicol neurotoxicity. Pediatr Infect Dis J 1988; 7: 358-359.
50. Tateishi J. Comparative study of neurotoxicity of clioquinol, ethambutol, isoniazid and chloramphenicol in dogs. Folia Psychiatr Neurol Jpn 1974; 28: 11-17.
51. Frank LA. Clinical pharmacology of rifampin. J Am Vet Med Assoc 1990; 197: 114-117.
52. Archer GL, Johnson JL, Vazquez GL et al. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis 1983; 5: S538-S542.
53. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983; 5: S407-S411.
54. Hachbarth CJ, Chambers HF, Sand MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 611-613.
55. Kadlec K, van Duijkeren E, Wagenaar JA et al. Molecular basis of rifampicin resistance in methicillin-resistant Staphylococcus pseudintermedius isolates from dogs. J Antimicrob Chemother 2011; 66: 1236-1242.
56. Baciewicz AM, Self TH, Bekemeyer WB. Update on rifampin drug interactions. Arch Intern Med 1987; 147: 565-568.
57. Guardabassi L, Houser GA, Frank LA et al. Guidelines for antimicrobial use in dogs and cats. In: Guardabassi L, Jensen LB, Kruse H, eds. Guide to Antimicrobial Use in Animals. Oxford: Blackwell Publishing Ltd, 2008; 183-206.
58. Noli C, Morris D. Guidelines on the use of systemic aminoglycosides in veterinary dermatology. Vet Dermatol 2011; 22: 378-380.
59. Schwarz S, Roberts MC, Werckenthin C et al. Tetracycline resistance in Staphylococcus spp. from domestic animals. Vet Microbiol 1998; 63: 217-227.
60. Rubin JE, Ball KR, Chirino-Trejo M. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus pseudintermedius isolated from various animals. Can Vet J 2011; 52: 153-157.
61. Trzcinski K, Cooper BS, Hryniewicz W et al. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2000; 45: 763-770.
62. Schwartz BS, Graber CJ, Diep BA et al. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA 300. Clin Infect Dis 2009; 48: 1483-1484.
63. Scott DW, Beningo KE, Miller WH et al. Efficacy of clindamycin hydrochloride capsules for the treatment of deep pyoderma due to Staphylococcus intermedius infection in dogs. Can Vet J 1998; 39: 753-756.
64. Littlewood JD, Lakhani KH, Paterson S et al. Clindamycin hydrochloride and clavulanate-amoxycillin in the treatment of canine superficial pyoderma. Vet Rec 1999; 144: 662-665.
65. Bloom PB, Rosser EJ. Efficacy of once-daily clindamycin hydrochloride in the treatment of superficial bacterial pyoderma in dogs. J Am Anim Hosp Assoc 2001; 37: 537-542.
66. Batzias GC, Delis GA, Athanasiou LV. Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs. Vet J 2005; 170: 339-345.
67. Saridomichelakis MN, Athansiou LV, Salame M et al. Serum pharmacokinetics of clindamycin hydrochloride in normal dogs when administered at two dosage regimens. Vet Dermatol 2011; 22: 429-435.
68. Lloyd DH, Lamport AI, Noble WC et al. Fluoroquinolone resistance in Staphylococcus intermedius. Vet Dermatol 1999; 10: 249-251.
69. Ganiere JP, Medaille C, Limet A et al. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas. Vet Dermatol 2001; 12: 171-175.
70. Venezia RA, Domaracki BE, Evans AM et al. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001; 48: 375-381.
71. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-1422.
72. Lin AE, Davies JE. Occurrence of highly fluoroquinolone-resistant and methicillin-resistant Staphylococcus aureus in domestic animals. Can J Microbiol 2007; 53: 925-929.
73. Murphy KM. The use of linezolid to treat methicillin-resistant staphylococcal infections in dogs and cats. Vet Dermatol 2008; 19: 110. (Abstract).
74. Weese JS. Issues regarding the use of vancomycin in companion animals. J Am Vet Med Assoc 2008; 233: 565-567.
75. Loeffler A, Cobb MA, Bond R. Comparison of a chlorhexidine and a benzoyl peroxide shampoo as sole treatment in canine superficial pyoderma. Vet Rec 2011; 169: 249.
76. Ascher F, Maynard L, Laurent J et al. Controlled trial of ethyl lactate and benzoyl peroxide shampoos in the management of canine surface pyoderma and superficial pyoderma. In: von Tscharner C, Halliwell REW, eds. Advances in Veterinary Dermatology, vol. 1, Philadelphia, PA:Baillière Tindall, 1990; 375-382.
77. Koch HJ, Vercelli A. Shampoos and other topical therapies. In: Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology, vol. 2, New York, NY: Pergamon Press, 1993; 409-411.
78. de Jaham C. Effects of an ethyl lactate shampoo in conjunction with a systemic antibiotic in the treatment of canine superficial bacterial pyoderma in an open-label, nonplacebo-controlled study. Vet Ther 2003; 4: 94-100.
79. Murayama N, Nagata M, Terada Y et al. Efficacy of a surgical scrub including 2% chlorhexidine acetate for canine superficial pyoderma. Vet Dermatol 2010; 21: 586-592.
80. Young R, Buckley L, McEwan N et al. Comparative in vitro efficacy of antimicrobial shampoos: a pilot study. Vet Dermatol 2012; 23: 36-40.
81. Murayama N, Terada Y, Okuaki M et al. Contact time of 2% chlorhexidine acetate for canine superficial pyoderma. Vet Dermatol, 2011; 22: 449-453.
82. Werner AH, Russel AD. Mupirocin, fusidic acid and bacitracin: activity, action and clinical uses of three topical antibiotics. Vet Dermatol 1999; 10: 225-240.
83. Rankin SC, O'Shea K, Rejman JJ et al. MIC range, MIC50 and MIC90 for nisin against Staphylococcus isolates from companion animals. Vet Dermatol 2007; 18: 190. (Abstract).
84. Frank LA, Kirzeder EM, Davis JA et al. Nisin impregnated wipes for the treatment of canine pyoderma and surface bacterial colonization. Vet Dermatol 2009; 20: 219. (Abstract).
85. Loeffler A, Baines SJ, Toleman MS et al. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets. J Antimicrob Chemother 2008; 62: 1301-1304.
86. Vali L, Davies SE, Lai LLG et al. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother 2008; 61: 524-532.
87. Hillier A, Pinchbeck LR, Bannerman T et al. Vet Dermatol 2007; 18: 182. (Abstract).
88. Frank LA, Black C, Kania SA et al. Carriage of methicillin resistant Staphylococcus pseudintermedius in dogs. Proceedings of the ASM Conferences: Staphylococci in Animals: Veterinary and Public Health Implications. London, UK, 2009, 32-33.
89. Laarhoven LM, de Heus P, van Luijn J et al. Longitudinal study on methicillin-resistant Staphylococcus pseudintermedius in households. PLoS One 2011; 6: e27788.
90. van Duijkeren E, Kamphuis M, van der Mije IC et al. Transmission of methicillin-resistant Staphylococcus pseudintermedius between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. Vet Microbiol 2011; 150: 338-343.
91. Tacconelli E, Johnson AP. National guidelines for decolonization of methicillin-resistant Staphylococcus aureus carriers: the implications of recent experience in the Netherlands. J Antimicrob Chemother 2011; 66: 2195-2198.
92. Fritz SA, Camins BC, Eisenstein KA et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol 2011; 32: 872-880.
93. Saijonmaa-Koulumies L, Parsons E, Lloyd DH. Elimination of Staphylococcus intermedius in healthy dogs by topical treatment with fusidic acid. J Small Anim Pract 1998; 39: 341-347.
94. Loeffler A, Pfeiffer DU, Lloyd DH et al. Meticillin-resistant Staphylococcus aureus carriage in UK veterinary staff and owners of infected pets: new risk groups. J Hosp Infect 2010; 74: 282-288.
95. Murphy CP, Reid-Smith RJ, Boerlin P et al. Escherichia coli and selected veterinary and zoonotic pathogens isolated from environmental sites in companion animal veterinary hospitals in southern Ontario. Can Vet J 2010; 51: 963-972.
96. Wagenvoort JH, Sluijsmans W, Penders RJ. Better environmental survival of outbreak vs. sporadic MRSA isolates. J Hosp Infect 2000; 45: 231-234.
97. Baines BJ, Loeffler A, Milsom S et al. Susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus and Staphylococcus intermedius isolated from dogs and cats to three antiseptics. Scientific Proceedings 2008, 51st British Small Animal Veterinary Association Congress, Birmingham, UK; 452.
98. Zubeir IE, Kanbar T, Alber J et al. Phenotypic and genotypic characteristics of methicillin/oxacillin-resistant Staphylococcus intermedius isolated from clinical specimens during routine veterinary microbiological examinations. Vet Microbiol 2007; 121: 170-176.
99. Steen S, Webb P. Differing patterns of antimicrobial sensitivity among meticillin-resistant coagulase-positive staphylococci isolated from canines. In: Warren S, ed. British Veterinary Dermatology Study Group Spring Meeting 2010; Birmingham, UK, 2010; 33.
100. Bemis DA, Jones RD, Frank LA et al. Evaluation of susceptibility test breakpoints used to predict mecA-mediated resistance in Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2009; 21: 53-58.
101. De Lucia M, Moodley A, Latronico F et al. Prevalence of canine methicillin resistant Staphylococcus pseudintermedius in a veterinary diagnostic laboratory in Italy. Res Vet Sci 2011; 91: 346-348.
102. Chrobak D, Kizerwetter-Swida M, Rzewuska M et al. Antibiotic resistance of canine Staphylococcus intermedius group (SIG)-practical implications. Pol J Vet Sci 2011; 14: 213-218.
103. Onuma K, Tanabe T, Sato H. Antimicrobial resistance of Staphylococcus pseudintermedius isolates from healthy dogs and dogs affected with pyoderma in Japan. Vet Dermatol 2012; 23: 17-22.